Nurix Therapeutics, Inc. stock is up 60.53% since 30 days ago. The next earnings date is Feb 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 1 PUT, 1 CALL.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy, is in Phase 1 clinical trials for gynecologic cancers, including ovarian, endometrial, and cervical cancer.